In a report issued on July 7, Marc Goodman from Leerink Partners maintained a Buy rating on Biohaven Pharmaceutical Holding Co (BHVN – Research Report). The company’s shares closed last Friday at $117.53, close to its 52-week high of $119.27.
According to TipRanks.com, Goodman is a 4-star analyst with an average return of 6.0% and a 52.8% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals.
Currently, the analyst consensus on Biohaven Pharmaceutical Holding Co is a Strong Buy with an average price target of $112.67, representing a -1.6% downside. In a report issued on July 7, Mizuho Securities also maintained a Buy rating on the stock with a $92.00 price target.
Biohaven Pharmaceutical Holding Co’s market cap is currently $7.65B and has a P/E ratio of -6.90. The company has a Price to Book ratio of -23.06.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.